What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 26x, you may consider Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) as a stock to potentially avoid with its 32.2x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.

With earnings growth that's superior to most other companies of late, Sunshine Guojian Pharmaceutical (Shanghai) has been doing relatively well. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

View our latest analysis for Sunshine Guojian Pharmaceutical (Shanghai)

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Sunshine Guojian Pharmaceutical (Shanghai).

What Are Growth Metrics Telling Us About The High P/E?

The only time you'd be truly comfortable seeing a P/E as high as Sunshine Guojian Pharmaceutical (Shanghai)'s is when the company's growth is on track to outshine the market.

If we review the last year of earnings growth, the company posted a terrific increase of 340%. Although, its longer-term performance hasn't been as strong with three-year EPS growth being relatively non-existent overall. So it appears to us that the company has had a mixed result in terms of growing earnings over that time.

Looking ahead now, EPS is anticipated to slump, contracting by 4.3% per year during the coming three years according to the three analysts following the company. With the market predicted to deliver 24% growth each year, that's a disappointing outcome.

In light of this, it's alarming that Sunshine Guojian Pharmaceutical (Shanghai)'s P/E sits above the majority of other companies. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a very good chance these shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the negative growth outlook.

What We Can Learn From Sunshine Guojian Pharmaceutical (Shanghai)'s P/E?

Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

We've established that Sunshine Guojian Pharmaceutical (Shanghai) currently trades on a much higher than expected P/E for a company whose earnings are forecast to decline. When we see a poor outlook with earnings heading backwards, we suspect the share price is at risk of declining, sending the high P/E lower. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

We don't want to rain on the parade too much, but we did also find 2 warning signs for Sunshine Guojian Pharmaceutical (Shanghai) (1 doesn't sit too well with us!) that you need to be mindful of.

Of course, you might also be able to find a better stock than Sunshine Guojian Pharmaceutical (Shanghai). So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com